Article
BTIG Maintains Buy on Nektar Therapeutics, Raises Price Target to $151
BTIG analyst Julian Harrison maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $118 to $151.
Comments
- No comments yet. Be the first to comment!